The Quantellect read.As of Nov 19, 2026, 7 active firms cover Amylyx Pharmaceuticals Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $19.00 to $57.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $40.71 sits 53% above the current $26.60. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.36 next quarter toward $-1.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$40.71
+53.1% upside
Average target across 7 active firms as of Nov 19, 2026 vs $26.60 current
Highest Target$57.00
Average Target$40.71
Lowest Target$19.00
Detailed analyst forecasts for AMLX
Showing 1–6 of 6 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate AMLX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AMLX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.38 – $-0.33 · 3 analysts · -2% YoY
Next period, 3 analysts expect Amylyx Pharmaceuticals Inc to earn $-0.36 a share (range $-0.38 – $-0.33), versus $-0.37 a year earlier. Full-year consensus is $-1.51, growing to $-1.13 the year after.
REVENUE · NEXT QUARTER
$731.0K
Range $0 – $1.5M · 3 analysts · +0% YoY
Revenue is expected to reach $731.0K (range $0 – $1.5M), +0.0% year-over-year. Full-year consensus is $55.6K, rising to $31.2M next year.
Top analysts covering Amylyx Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AMLX.
#1
Joel Beatty
Baird · Rank #71
Buy
$52.00+95.5% to target
Overall win rate
50%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$55.00+106.8% to target
Overall win rate
45%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #160
Buy
$39.00+46.6% to target
Overall win rate
47%
+ Follow
#4
Graig Suvannavejh
Mizuho · Rank #239
Buy
$39.00+46.6% to target
Overall win rate
40%
+ Follow
#5
Marc Goodman
Leerink Partners · Rank #251
Buy
$20.00-24.8% to target
Overall win rate
46%
+ Follow
AMLX stock forecast FAQ
What is AMLX's average 12-month price target?+
The 7 active firms with a live target average $40.71 for Amylyx Pharmaceuticals Inc over the next 12 months, ranging from a $57.00 high to a $19.00 low, as of Nov 19, 2026.
Is AMLX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AMLX?+
The Street-high target is $57.00 (Guggenheim), and the Street-low is $19.00 (B of A Securities). The average of all 7 active-firm targets is $40.71.
How many active Wall Street firms cover AMLX?+
7 active firms have a recognized rating on Amylyx Pharmaceuticals Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AMLX?+
Among analysts who currently cover AMLX, Joel Beatty of Baird has the strongest overall Quantellect track record (Rank #71). Their current call is Buy with a $52.00 target.
What is Amylyx Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.38 – $-0.33) across 3 analysts. Full-year EPS is projected at $-1.51, rising to $-1.13 the following year.
How much revenue is Amylyx Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $731.0K (range $0 – $1.5M). Full-year revenue is projected at $55.6K, growing to $31.2M next year.
Have analysts been upgrading or downgrading AMLX lately?+
As of Nov 19, 2026, 7 of 7 active firms rate AMLX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AMLX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.